Home  »  Hot Stocks   »  Buy or Sell Editas Medicine Inc. (EDIT) Stock Now ...

Buy or Sell Editas Medicine Inc. (EDIT) Stock Now | Don’t Try to Be a Top Gun

Editas Medicine Inc. (NASDAQ:EDIT) went up by 7.95% from its latest closing price compared to the recent 1-year high of $21.59. The company’s stock price has collected 6.00% of gains in the last five trading sessions.

Is It Worth Investing in Editas Medicine Inc. (NASDAQ :EDIT) Right Now?

Plus, the 36-month beta value for EDIT is at 1.85. Opinions of the stock are interesting as 4 analysts out of 19 who provided ratings for Editas Medicine Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 11 rated it as “hold,” and 3 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

EDIT currently public float of 68.43M and currently shorts hold a 31.64% ratio of that float. Today, the average trading volume of EDIT was 1.88M shares.

EDIT’s Market Performance

EDIT stocks went up by 6.00% for the week, with a monthly drop of -4.02% and a quarterly performance of -24.79%, while its annual performance rate touched -51.35%. The volatility ratio for the week stands at 6.16% while the volatility levels for the past 30 days are set at 7.08% for Editas Medicine Inc. The simple moving average for the period of the last 20 days is 3.31% for EDIT stocks with a simple moving average of -31.45% for the last 200 days.

Analysts’ Opinion of EDIT

Many brokerage firms have already submitted their reports for EDIT stocks, with Citigroup repeating the rating for EDIT by listing it as a “Neutral.” The predicted price for EDIT in the upcoming period, according to Citigroup is $11 based on the research report published on December 13th of the previous year 2022.

Credit Suisse, on the other hand, stated in their research note that they expect to see EDIT reach a price target of $13. The rating they have provided for EDIT stocks is “Neutral” according to the report published on December 06th, 2022.

Oppenheimer gave a rating of “Perform” to EDIT, setting the target price at $12 in the report published on November 18th of the previous year.

EDIT Trading at -9.10% from the 50-Day Moving Average

After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.11% of loss for the given period.

Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 6.16%, as shares sank -3.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.63% lower at present.

During the last 5 trading sessions, EDIT rose by +6.00%, which changed the moving average for the period of 200-days by -55.29% in comparison to the 20-day moving average, which settled at $8.53. In addition, Editas Medicine Inc. saw -0.45% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EDIT starting from ROBERTSON MICHELLE, who sale 1,752 shares at the price of $8.16 back on Jan 10. After this action, ROBERTSON MICHELLE now owns 80,530 shares of Editas Medicine Inc., valued at $14,296 using the latest closing price.

Eaton Bruce, the EVP, CHIEF BUSINESS OFFICER of Editas Medicine Inc., sale 102 shares at $10.23 during a trade that took place back on Dec 05, which means that Eaton Bruce is holding 64,636 shares at $1,043 based on the most recent closing price.

Stock Fundamentals for EDIT

Current profitability levels for the company are sitting at:

  • -756.13 for the present operating margin
  • +80.22 for the gross margin

The net margin for Editas Medicine Inc. stands at -753.61. Equity return is now at value -41.30, with -33.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 10.82.

Is SSR Mining Inc. (SSRM) a Keeper?

SSR Mining Inc. (NASDAQ:SSRM) went down by -3.03% from its latest closing price compared to the recent 1-year high of $24.58. The company’s stock price